Balboa Wealth Partners Reduces Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Balboa Wealth Partners trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,452 shares of the biopharmaceutical company’s stock after selling 47 shares during the quarter. Balboa Wealth Partners’ holdings in Regeneron Pharmaceuticals were worth $1,034,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Wintrust Investments LLC boosted its stake in Regeneron Pharmaceuticals by 187.1% in the fourth quarter. Wintrust Investments LLC now owns 201 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 131 shares during the last quarter. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares in the last quarter. Bronte Capital Management Pty Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 11.5% during the 4th quarter. Bronte Capital Management Pty Ltd. now owns 152,783 shares of the biopharmaceutical company’s stock valued at $108,832,000 after buying an additional 15,741 shares in the last quarter. Avantax Advisory Services Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 33.1% during the 4th quarter. Avantax Advisory Services Inc. now owns 1,624 shares of the biopharmaceutical company’s stock valued at $1,157,000 after buying an additional 404 shares in the last quarter. Finally, AGF Management Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 281.2% during the 4th quarter. AGF Management Ltd. now owns 1,277 shares of the biopharmaceutical company’s stock valued at $910,000 after buying an additional 942 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Sanford C. Bernstein dropped their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, Bank of America restated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $689.50 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The stock has a market capitalization of $75.38 billion, a price-to-earnings ratio of 18.01, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a fifty day moving average of $696.62 and a 200-day moving average of $841.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the company earned $11.86 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.